Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Caring Brands Incorporation ( (CABR) ) just unveiled an announcement.
On December 31, 2025, Caring Brands Inc. signed an exclusive worldwide license agreement with Itonis Inc., granting Caring Brands full rights to manufacture, market and sell Itonis’s over‑the‑counter nausea relief product Emesyl, with Itonis providing technical, formulation, historical sales and intellectual property information to support the product’s relaunch. Announced publicly on January 5, 2026, the deal positions Caring Brands to expand its over‑the‑counter health portfolio into the global nausea treatment market, which is projected to exceed USD 6.23 billion in 2025, under a royalty structure based on net sales and a mechanism allowing Caring Brands to earn equity in Itonis tied to revenue milestones, while also introducing performance thresholds that could end its exclusivity if sales remain weak over four consecutive quarters.
More about Caring Brands Incorporation
Caring Brands Inc. is a health and wellness company with a growing portfolio of unique, patented and clinically validated products focused on skin and hair growth. The company plans to launch five products over the next two years while continuing to in‑license additional assets, and currently generates revenue from Hair Enzyme Booster for hair loss and Photocil for psoriasis and vitiligo through direct U.S. sales and licensees in India, with additional pipeline opportunities including eczema treatment CB‑101 and NoStingz, a sunscreen designed to prevent jellyfish stings.
Average Trading Volume: 261,284
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.74M
For a thorough assessment of CABR stock, go to TipRanks’ Stock Analysis page.